Condition Directory

Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Cancer. Browse Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

50397

Shown on this page

Current sort

How Cancer studies are organized in the registry

“Cancer” is the broadest term in the registry, and most oncology records list a specific cancer type rather than the umbrella word. If you are researching a particular diagnosis, the dedicated pages for that cancer type usually give a cleaner result set. Tumor-agnostic and basket studies are the exception — they often appear under generic terms instead of a single organ site.

Terms that often appear in related listings

solid tumor advanced solid tumors metastatic basket trial

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1129–1140 of 50,397 matching trials for Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Glioblastoma Multiforme, Recurrent Glioblastoma
Interventions: TheraSphere GBM; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 6 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Cabozantinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions: Zanzalintinib, Everolimus; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Pancreatic Adenocarcinoma, Metastatic
Interventions: Nab-paclitaxel, Gemcitabine, VCN-01; Drug · Genetic
Lead sponsor: Theriva Biologics SL; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Newport Beach, California • Sacramento, California • Louisville, Kentucky + 4 more

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab, Sonrotoclax, Zanubrutinib; Procedure · Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Aging, Endothelial Dysfunction, Men
Interventions: Blueberry Powder, Placebo Powder; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Adult Acute Myeloid Leukemia
Interventions: mocravimod; Drug
Lead sponsor: Priothera SAS; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 21
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 18 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
Interventions: Orca-Q; Biological
Lead sponsor: University of Florida; Other
Eligibility: Up to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Gainesville, Florida • Miami, Florida • St. Petersburg, Florida

Conditions: Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 7 more

Conditions: Breast Cancer Recurrent
Interventions: Functional Precision Oncology; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Breast Cancer
Interventions: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 57
States / cities: Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more

Conditions: Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Interventions: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D), STX-721/PFL-721 (Escalated) with platinum-based chemotherapy, STX-721/PFL-721 with platinum-based chemotherapy; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 6 more

About this Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cancer clinical trials

How Cancer studies are organized in the registry

Filter and sort this condition

Live official records

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

About this Cancer clinical trials directory page